Venetoclax Combined With Azactidine in the Treatment of ALAL

Key facts

Sponsor

Sheng-Li Xue, MD

Intervention

Venetoclax(drug)

Enrollment

23 enrolled

Eligibility

15 years · All sexes

Timeline

2023 – 2026

Study locations (1)

• The First Affliated Hospital of Soochow University, Suzhou, China

Collaborators

Jining Medical University · The Second People's Hospital of Huai'an · The First Affiliated Hospital of Bengbu Medical University · Affiliated Hospital of Nantong University · Suzhou Hospital of Traditional Chinese Medicine · Northern Jiangsu People's Hospital · Pingdingshan first people's Hospital · The Second Affiliated Hospital of Wannan Medical College · Canglang Hospital of Suzhou

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute leukemia of ambiguous lineage

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07046078
  Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
  Fred Hutchinson Cancer Center
• RECRUITINGPHASE2NCT06317662
  Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
  National Cancer Institute (NCI)
• RECRUITINGPHASE2NCT06013423
  Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
  Fred Hutchinson Cancer Center
• ACTIVE NOT RECRUITINGPHASE2NCT05761171
  A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
  Children's Oncology Group
• RECRUITINGPHASE2NCT05735717
  MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
  Masonic Cancer Center, University of Minnesota
• ACTIVE NOT RECRUITINGPHASE1NCT04898894
  Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
  St. Jude Children's Research Hospital
• RECRUITINGPHASE2NCT04099966
  AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
  Mitchell Cairo
• RECRUITINGPHASE2NCT04440267
  Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
  Institute of Hematology & Blood Diseases Hospital, China

See all trials for Acute leukemia of ambiguous lineage →